SPONSOR
Daiichi Sankyo
Total Trials
4
Recruiting
4
Phases
Phase 3, Phase 1, Phase 2
Conditions studied: LeukemiaAdvanced Solid TumorMalignant Solid TumorNon-small Cell Lung CancerEndometrial Cancer
Daiichi Sankyo is a clinical research sponsor with 4 registered studies on ClinicalTrials.gov, of which 4 are actively recruiting participants. Research covers conditions including Leukemia, Advanced Solid Tumor, Malignant Solid Tumor, Non-small Cell Lung Cancer.
The trial portfolio spans Phase 3, Phase 1, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Daiichi Sankyo
How many clinical trials has Daiichi Sankyo sponsored?
ClinicalMetric currently tracks 4 clinical trials sponsored by Daiichi Sankyo, of which 4 are actively recruiting participants. These trials cover conditions including Leukemia, Advanced Solid Tumor, Malignant Solid Tumor. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Daiichi Sankyo research focus on?
Daiichi Sankyo clinical trials span Leukemia, Advanced Solid Tumor, Malignant Solid Tumor, Non-small Cell Lung Cancer, Endometrial Cancer. The research pipeline includes Phase 3, Phase 1, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Daiichi Sankyo clinical trial?
To participate in a Daiichi Sankyo trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Daiichi Sankyo trials with current recruitment status updated daily.
Clinical Trials by Daiichi Sankyo
NCT06578247 Phase 3
Recruiting
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
NCT04145622 Phase 1, Phase 2
Recruiting
Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors
Advanced Solid Tumor
NCT06809764
Recruiting
Clinical Effectiveness and Safety of Trastuzumab Deruxtecan (T-DXd) in Chinese Patients With HER2m NSCLC (RERUN)
Non-small Cell Lung Cancer
NCT07022483 Phase 3
Recruiting
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
Endometrial Cancer
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology